加载中…
Anti-BDCA-2 Antibody (Litifilimab Biosimilar) is a research-use biosimilar antibody expressed in HEK293. The source page specifies target BDCA-2, reactivity Human/Cynomolgus, isotype Human IgG1-Kappa, source-listed application ELISA.
BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)-α/β-controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potently inhibits secretion of IFN-α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells.
